FIELD: biotechnology.
SUBSTANCE: invention relates to a multispecific molecule containing a CD22 antigen binding domain and a CD79b antigen specific binding domain.
EFFECT: invention can be effectively used in treating an autoimmune disease.
9 cl, 9 tbl, 11 ex, 34 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES WITH CD45 AND CD79 SPECIFICITY | 2015 |
|
RU2747980C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| ANTAGONISTIC ANTIBODIES THAT BIND TO HUMAN TGFβ1, TGFβ2 AND TGFβ3, AND THEIR USE IN TREATMENT OF LUNG FIBROSIS | 2017 |
|
RU2746926C2 |
